CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Clinical trials for CHRONIC MYELOMONOCYTIC LEUKEMIA-1 explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOMONOCYTIC LEUKEMIA-1 trials appear
Sign up with your email to follow new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy battle for blood cancer patients
Disease control OngoingThis study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults with thes…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
Targeted therapy duo takes aim at hard-to-treat blood cancer
Disease control OngoingThis study tests a combination of two drugs—tagraxofusp and decitabine—for people with chronic myelomonocytic leukemia or related high-risk blood disorders. Tagraxofusp delivers a toxin directly to cancer cells, while decitabine is a chemotherapy that stops cancer growth. The goa…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New drug duo aims to halt rare blood cancers
Disease control OngoingThis study tests a new drug, seclidemstat, combined with a standard treatment (azacitidine) for people with certain blood cancers (myelodysplastic syndromes and chronic myelomonocytic leukemia). The goal is to find the best dose and see if the combination can shrink or control th…
Matched conditions: CHRONIC MYELOMONOCYTIC LEUKEMIA-1
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:55 UTC